Transformed Bioactive Compounds
Cellbitec is a biotechnology company focused on the discovery of new active ingredients of plant origin with applications in the fields of biomedicine and nutrition by providing a beneficial effect on human health, specifically in the treatment or prevention of colorectal cancer, metabolic or neurodegenerative diseases.
Our History
2017
The businessman Francisco Bermúdez Pérez, in order to enhance his collaboration with the Biomedical Research Centre (CIBM) of the University of Granada, founded the company with the aim of developing research aimed at the field of biomedicine, to obtain plant extracts with a high content of molecules with high antioxidant power and/or anti-cancer capacity.
Following its initial capital investment, the company begins a detailed search for technologies developed in public centres and research institutes and universities in Europe and Latin America.
2018
As a result of the intense collaboration with the CIBM, four bioactive molecules of plant origin with high antioxidant and anticancer activity have been identified.
These encouraging results have led to the creation of a joint research consortium, in which IFAPA is also involved, to further develop the R&D work….
In December 2018, the project ‘Plant-based nano-nutraceuticals with anti-tumour activity against colon cancer’ led by Cellbitec and involving the CIBM-UGR and IFAPA, received support from the State Programme for R+D+i Oriented to the Challenges of Society.
This programme has public funding from the European Union’s ERDF funds and is managed by the Spanish Ministry of Science, Innovation and Universities.
2019
In March 2019, a Doctor Torres Quevedo will join the Cellbitec team to lead and promote the company’s own R&D activities and to coordinate the work being carried out in collaboration with CIBM-UGR and IFAPA.
This incorporation is supported by the State Programme for the Promotion of Talent and its Employability in R&D&I, managed by the Ministry of Science, Innovation and Universities of the Spanish Government.
In 2019, the company decided to focus on protecting the intellectual and industrial property of both the bioactive compounds of botanical origin identified in the R&D work and the extraction methodology of the molecules responsible for the anti-cancer activity.
In 2019, the company decided to focus on protecting the intellectual and industrial property of both the bioactive compounds of botanical origin identified in the R&D work and the extraction methodology of the molecules responsible for the anti-cancer activity.
The CELLBITEC team continues to strengthen further and begins an expansion phase, broadening its shareholder base through a Series A funding round, prepares to begin PHASE I clinical development of its plant-based phytochemicals, in order to validate the safety and toxicology results obtained in the PRECLINICAL PHASE.
2020
While this work is being carried out, CELLBITEC is initiating work to evaluate other possible indications for its phytochemical compounds, and to carry out studies of these compounds applied for their potential application in other sectors of the population.
2021
Cellbitec is extending its applications to the field of neurodegenerative diseases thanks to a new collaboration with the Margarita Salas Biological Research Centre, part of the Spanish National Research Council (CSIC).
2022
With the aim of further validating our bioactive molecules, the project for the ‘PRECLINICAL VALIDATION OF NPS FUNCTIONALISED WITH EUPHORBIA LATHYRIX BIOMOLECULES AS A NEW SELECTIVE THERAPY FOR CRC’ is proposed by the Instituto de Salud Carlos III and the Centro para el Desarrollo Tecnológico y la Innovación (Centre for Technological Development and Innovation) for innovations in personalised medicine and advanced therapies.
2023
Based on previous results, the company has decided to continue its efforts in the search for new molecules with applications in metabolic and neurodegenerative diseases. The project ‘NEW FUNCTIONAL INGREDIENTS DERIVED FROM THE FRUIT OF ARGANIA SPINOSA L. AND THEIR POTENTIAL USE IN BIOTECHNOLOGY AND BIOMEDICAL INDUSTRY’ is developed with the CIBM-UGR AND CIB-CSIC.
Scientific Committee
Cellbitec’s decisions are supported by a scientific committee, composed of leading researchers specialised in the fields of medicine, pharmacy, plant biology, agronomy, nanotechnology, oncology and human nutrition.
Professor of the Department of Human Anatomy and Embryology at the University of Granada
Professor, Department of Human Anatomy and Embryology. Deputy Director of the Biomedical Research Centre
PhD in Physiology. Professor, Department of Physiology, University of Granada
PhD in Industrial Chemistry. Researcher in the BioNanoMetals Group at the University of Granada
PhD in Materials Science. Professor and Researcher in the BioNanoMetals Group at the University of Granada
PhD in Biomedicine in Cellbitec
PhD in Nutrition and Degree in Biology. Lecturer in the Department of Physiology at the University of Granada
PhD in Chemical Sciences. Researcher in neurodegenerative diseases at the Margarita Salas Biological Research Centre (CSIC)
Researcher in neurodegenerative diseases at the Margarita Salas Biological Research Centre (CSIC)
PhD in Biology.
Research scientist at the CIB Margarita Salas CSIC
Director of the Margarita Salas Biological Research Centre-CSIC
Research scientist at the CIB Margarita Salas CSIC
Director of the Margarita Salas Biological Research Centre-CSIC